Posted by Michael Wonder on 12 Feb 2018
NICE backs EUSA’s kidney cancer drug Fotivda
12 February 2018 - NICE) has published draft guidelines backing use of EUSA Pharma’s Fotivda as a first-line treatment option for advanced renal cell carcinoma.
The drug, which won approval in Europe in August last year, is an oral, once-daily, potent selective vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI) that works by reducing the supply of blood to the tumour to deny it food and oxygen.
In clinical trials, patients treated with Fotivda (tivozanib) experienced superior progression free survival - 11.9 versus 9.1 months in the overall population and 12.7 versus 9.1 months in treatment naïve patients - versus Bayer’s Nexavar (sorafenib).
